The predictive value of serum galectin 3 for abdominal aortic calcification in maintenance hemodialysis patients: A

Zhiyu Wang1, Zijin Chen1, Xiaobo Ma1

  • 1Division of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Hemodialysis International. International Symposium on Home Hemodialysis
|February 13, 2020
PubMed

Insights

Serum Galectin-3 (Gal-3) shows significant predictive value for severe abdominal aortic calcification (AAC) and its progression in patients undergoing maintenance hemodialysis (MHD). This finding suggests Gal-3 may serve as a key biomarker for vascular calcification in ESRD patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Biomarker Discovery

Background:

  • Heterotopic vascular calcification is a frequent complication in maintenance hemodialysis (MHD) patients.
  • Galectin-3 (Gal-3) has been linked to cardiovascular calcification, prompting investigation into its role in MHD patients.

Purpose of the Study:

  • To investigate the predictive value of serum Gal-3 for severe abdominal aortic calcification (AAC) and AAC progression.
  • To assess Gal-3 as a potential biomarker for vascular calcification in end-stage renal disease (ESRD) patients on MHD.

Main Methods:

  • A prospective cohort study followed 152 MHD patients for 3 years with two AAC assessments.
  • Serum Gal-3 levels were measured using quantitative ELISA kits.
  • Statistical analysis included logistic regression and ROC curve analysis.

Main Results:

  • Serum Gal-3 was identified as an independent risk factor for severe AAC and AAC progression.
  • ROC curve analysis confirmed the significant prognostic value of serum Gal-3 for predicting severe AAC and its progression within 3 years.

Conclusions:

  • Serum Gal-3 is correlated with vascular calcification in ESRD patients.
  • Gal-3 may serve as a potential biomarker for vascular calcification in MHD patients.
Abstract